Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels: Post hoc analysis of the GO-FORTH study

Yoshiya Tanaka, Masayoshi Harigai, Tsutomu Takeuchi, Hisashi Yamanaka, Naoki Ishiguro, Kazuhiko Yamamoto, Yutaka Ishii, Hiroshi Nakajima, Daniel Baker, Nobuyuki Miyasaka, Takao Koike

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives: To assess the influence of golimumab dosage and disease activity on joint destruction in patients with active rheumatoid arthritis (RA) in the GO-FORTH study. Methods: Efficacy was compared among groups given basal methotrexate plus placebo, golimumab (50 mg), or golimumab (100 mg) with stratification by high (HDA) or moderate (MDA) baseline disease activity and by high or low baseline C-reactive protein (CRP). Results: Among HDA or high CRP patients, the mean change of the total Sharp score was 3.48 and 3.41 in the placebo group, 1.94 and 2.71 in the 50 mg group, and 0.39 and 1.15 in the 100 mg group, respectively. The percentage of progression-free patients with HDA or high CRP was 40.4% and 40.0%, 43.1% and 38.2%, and 69.8% and 61.5%, respectively. Among MDA or low CRP patients, both golimumab doses showed similar prevention of joint destruction. Among HDA or high CRP patients, a shorter disease duration and higher TSS/disease duration ratio were associated with joint destruction. Conclusion: Both doses of golimumab (50 or 100 mg) prevented joint destruction in MDA or low CRP patients, but 100 mg was better for HDA or high CRP patients with a shorter disease duration or higher TSS/disease duration ratio.

Original languageEnglish
JournalModern Rheumatology
DOIs
Publication statusAccepted/In press - 2015 Oct 9

Fingerprint

C-Reactive Protein
Joints
Placebos
Methotrexate
Rheumatoid Arthritis
golimumab

Keywords

  • Golimumab
  • High disease activity
  • Japanese
  • Rheumatoid arthritis
  • Total Sharp score

ASJC Scopus subject areas

  • Rheumatology

Cite this

Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels : Post hoc analysis of the GO-FORTH study. / Tanaka, Yoshiya; Harigai, Masayoshi; Takeuchi, Tsutomu; Yamanaka, Hisashi; Ishiguro, Naoki; Yamamoto, Kazuhiko; Ishii, Yutaka; Nakajima, Hiroshi; Baker, Daniel; Miyasaka, Nobuyuki; Koike, Takao.

In: Modern Rheumatology, 09.10.2015.

Research output: Contribution to journalArticle

Tanaka, Yoshiya ; Harigai, Masayoshi ; Takeuchi, Tsutomu ; Yamanaka, Hisashi ; Ishiguro, Naoki ; Yamamoto, Kazuhiko ; Ishii, Yutaka ; Nakajima, Hiroshi ; Baker, Daniel ; Miyasaka, Nobuyuki ; Koike, Takao. / Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels : Post hoc analysis of the GO-FORTH study. In: Modern Rheumatology. 2015.
@article{5cf2c0fe298a4578b8aa20939c03b376,
title = "Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels: Post hoc analysis of the GO-FORTH study",
abstract = "Objectives: To assess the influence of golimumab dosage and disease activity on joint destruction in patients with active rheumatoid arthritis (RA) in the GO-FORTH study. Methods: Efficacy was compared among groups given basal methotrexate plus placebo, golimumab (50 mg), or golimumab (100 mg) with stratification by high (HDA) or moderate (MDA) baseline disease activity and by high or low baseline C-reactive protein (CRP). Results: Among HDA or high CRP patients, the mean change of the total Sharp score was 3.48 and 3.41 in the placebo group, 1.94 and 2.71 in the 50 mg group, and 0.39 and 1.15 in the 100 mg group, respectively. The percentage of progression-free patients with HDA or high CRP was 40.4{\%} and 40.0{\%}, 43.1{\%} and 38.2{\%}, and 69.8{\%} and 61.5{\%}, respectively. Among MDA or low CRP patients, both golimumab doses showed similar prevention of joint destruction. Among HDA or high CRP patients, a shorter disease duration and higher TSS/disease duration ratio were associated with joint destruction. Conclusion: Both doses of golimumab (50 or 100 mg) prevented joint destruction in MDA or low CRP patients, but 100 mg was better for HDA or high CRP patients with a shorter disease duration or higher TSS/disease duration ratio.",
keywords = "Golimumab, High disease activity, Japanese, Rheumatoid arthritis, Total Sharp score",
author = "Yoshiya Tanaka and Masayoshi Harigai and Tsutomu Takeuchi and Hisashi Yamanaka and Naoki Ishiguro and Kazuhiko Yamamoto and Yutaka Ishii and Hiroshi Nakajima and Daniel Baker and Nobuyuki Miyasaka and Takao Koike",
year = "2015",
month = "10",
day = "9",
doi = "10.3109/14397595.2015.1086041",
language = "English",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels

T2 - Post hoc analysis of the GO-FORTH study

AU - Tanaka, Yoshiya

AU - Harigai, Masayoshi

AU - Takeuchi, Tsutomu

AU - Yamanaka, Hisashi

AU - Ishiguro, Naoki

AU - Yamamoto, Kazuhiko

AU - Ishii, Yutaka

AU - Nakajima, Hiroshi

AU - Baker, Daniel

AU - Miyasaka, Nobuyuki

AU - Koike, Takao

PY - 2015/10/9

Y1 - 2015/10/9

N2 - Objectives: To assess the influence of golimumab dosage and disease activity on joint destruction in patients with active rheumatoid arthritis (RA) in the GO-FORTH study. Methods: Efficacy was compared among groups given basal methotrexate plus placebo, golimumab (50 mg), or golimumab (100 mg) with stratification by high (HDA) or moderate (MDA) baseline disease activity and by high or low baseline C-reactive protein (CRP). Results: Among HDA or high CRP patients, the mean change of the total Sharp score was 3.48 and 3.41 in the placebo group, 1.94 and 2.71 in the 50 mg group, and 0.39 and 1.15 in the 100 mg group, respectively. The percentage of progression-free patients with HDA or high CRP was 40.4% and 40.0%, 43.1% and 38.2%, and 69.8% and 61.5%, respectively. Among MDA or low CRP patients, both golimumab doses showed similar prevention of joint destruction. Among HDA or high CRP patients, a shorter disease duration and higher TSS/disease duration ratio were associated with joint destruction. Conclusion: Both doses of golimumab (50 or 100 mg) prevented joint destruction in MDA or low CRP patients, but 100 mg was better for HDA or high CRP patients with a shorter disease duration or higher TSS/disease duration ratio.

AB - Objectives: To assess the influence of golimumab dosage and disease activity on joint destruction in patients with active rheumatoid arthritis (RA) in the GO-FORTH study. Methods: Efficacy was compared among groups given basal methotrexate plus placebo, golimumab (50 mg), or golimumab (100 mg) with stratification by high (HDA) or moderate (MDA) baseline disease activity and by high or low baseline C-reactive protein (CRP). Results: Among HDA or high CRP patients, the mean change of the total Sharp score was 3.48 and 3.41 in the placebo group, 1.94 and 2.71 in the 50 mg group, and 0.39 and 1.15 in the 100 mg group, respectively. The percentage of progression-free patients with HDA or high CRP was 40.4% and 40.0%, 43.1% and 38.2%, and 69.8% and 61.5%, respectively. Among MDA or low CRP patients, both golimumab doses showed similar prevention of joint destruction. Among HDA or high CRP patients, a shorter disease duration and higher TSS/disease duration ratio were associated with joint destruction. Conclusion: Both doses of golimumab (50 or 100 mg) prevented joint destruction in MDA or low CRP patients, but 100 mg was better for HDA or high CRP patients with a shorter disease duration or higher TSS/disease duration ratio.

KW - Golimumab

KW - High disease activity

KW - Japanese

KW - Rheumatoid arthritis

KW - Total Sharp score

UR - http://www.scopus.com/inward/record.url?scp=84945242829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945242829&partnerID=8YFLogxK

U2 - 10.3109/14397595.2015.1086041

DO - 10.3109/14397595.2015.1086041

M3 - Article

C2 - 26471830

AN - SCOPUS:84945242829

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

ER -